AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Kalaris Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00P80SH43
1.87▼ 0.12 (-6.03%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.99
Day's Range
1.87 – 1.99
52-Week Range
1.87 – 11.88
Volume
25.4K
Avg Volume
83.2K
Share Statistics
Shares Outstanding
Employees
20
Exchange
XNAS
Listed
2025-03-19
Share count as of August 4, 2026

Kalaris Therapeutics, Inc. Common Stock (KLRS) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Kalaris Therapeutics, Inc. Common Stock (KLRS)
What is Kalaris Therapeutics, Inc. Common Stock's Market Cap?
Kalaris Therapeutics, Inc. Common Stock's Market Cap is $44.5M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Enterprise Value?
Kalaris Therapeutics, Inc. Common Stock's Enterprise Value is -$49.0M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's EV / EBITDA?
Kalaris Therapeutics, Inc. Common Stock's EV / EBITDA is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Net Income (TTM)?
Kalaris Therapeutics, Inc. Common Stock's Net Income (TTM) is -$44.3M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's EBITDA?
Kalaris Therapeutics, Inc. Common Stock's EBITDA is -$47.7M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Kalaris Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.86, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Net Debt?
Kalaris Therapeutics, Inc. Common Stock's Net Debt is -$93.5M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · KLRSAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development (including $15, $12, $30 and $25 for a related party)
General and administrative (including $93, $37, $160 and $188 for a related party)
Total operating expenses
Loss from operations
Other income (expense), net:
Change in fair value of tranche liability (including $0, $0, $0 and $331 for a related party)
Change in fair value of derivative liabilities (including $0, $0, $0 and $1,165 for a related party)
Interest expense (including $0, $0, $0 and $1,384 for a related party)
Loss on extinguishment and on issuance of convertible promissory notes (including $0, $0, $0 and $169 for a related party)
Other income, net
Total other income, net
Net loss
Net loss per share attributable to common stockholders - basic
Net loss per share attributable to common stockholders - diluted